← Leaderboards
Marie Bleakley
Fred Hutchinson Cancer Center
$9,428,742
Attributed
$13,128,031
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,128,031 · 6
By mechanism
RC2$4,661,966 · 1
P01$4,621,313 · 1
R01$2,736,613 · 1
K23$849,990 · 1
P30$258,149 · 2
Top collaborators
- Stanley R Riddell5 shared
- Sergei Doulatov3 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Stanley R Riddell$31,084,866
- Hans-Peter Kiem$98,160,227
- Geoffrey Roger Hill$15,826,079
- Motoko Koyama$1,311,574
- Scott Nicholas Furlan$1,435,661
Others in their field
Top investigators on “Immunotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,653,178
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$111,361,061
- Robert H Vonderheide · University Of Pennsylvania$84,159,371
- Sharon A Nachman · Johns Hopkins University$74,725,055
- Todd A Alonzo · University Of Colorado Denver/Hsc Denver$72,436,447
Research focus
ImmunotherapyCellsT-LymphocyteLeukemiaClinical TrialsStem CellsImmuneImmunityImmunotherapeutic AgentT-Cell ReceptorPathogenResearch PersonnelIncidenceTransplantationPreventRelapseFuturePeripheral Blood Stem CellNovel StrategiesOpportunistic InfectionsAntigensReconstitutionRecurrenceAcute Leukemia
Grant awards (22)
Development of Innovative Resources to Advance MDS Research$1,574,993
RC2 · FY2025 · DK · contact PI
Cancer Immunology$92,233
P30 · FY2025 · CA · contact PI
Development of Innovative Resources to Advance MDS Research$1,511,993
RC2 · FY2024 · DK · contact PI
Research Program: Cancer Immunology$82,957
P30 · FY2024 · CA · contact PI
Development of Innovative Resources to Advance MDS Research$1,574,980
RC2 · FY2023 · DK · contact PI
Research Program: Cancer Immunology$82,959
P30 · FY2023 · CA · contact PI
Prevention of Graft-Versus-Host-Disease in the Era of Adoptive Immunotherapy$885,028
P01 · FY2022 · CA · contact PI
Prevention of Graft-Versus-Host-Disease in the Era of Adoptive Immunotherapy$893,343
P01 · FY2021 · CA · contact PI
Prevention of Graft-Versus-Host-Disease in the Era of Adoptive Immunotherapy$327,515
P01 · FY2021 · CA · contact PI
Prevention of Graft-Versus-Host-Disease in the Era of Adoptive Immunotherapy$884,291
P01 · FY2020 · CA · contact PI
Prevention of Graft-Versus-Host-Disease in the Era of Adoptive Immunotherapy$797,767
P01 · FY2019 · CA · contact PI
Prevention of Graft-Versus-Host-Disease in the Era of Adoptive Immunotherapy$833,369
P01 · FY2018 · CA · contact PI
Naive T cell depletion to prevent graft-versus-host disease$539,649
R01 · FY2018 · HL · contact PI
Naive T cell depletion to prevent graft-versus-host disease$539,649
R01 · FY2017 · HL · contact PI
Naive T cell depletion to prevent graft-versus-host disease$539,649
R01 · FY2016 · HL · contact PI
Naive T cell depletion to prevent graft-versus-host disease$531,554
R01 · FY2015 · HL
Allogeneic stem cell transplant with grafts depleted of naive T cells for leukemi$170,100
K23 · FY2015 · CA · contact PI
Naive T cell depletion to prevent graft-versus-host disease$586,112
R01 · FY2014 · HL
Allogeneic stem cell transplant with grafts depleted of naive T cells for leukemi$170,100
K23 · FY2014 · CA · contact PI
Allogeneic stem cell transplant with grafts depleted of naive T cells for leukemi$170,100
K23 · FY2013 · CA · contact PI
Allogeneic stem cell transplant with grafts depleted of naive T cells for leukemi$170,100
K23 · FY2012 · CA · contact PI
Allogeneic stem cell transplant with grafts depleted of naive T cells for leukemi$169,590
K23 · FY2011 · CA · contact PI